高级检索
当前位置: 首页 > 详情页

Linderalactone inhibits human lung cancer growth by modulating the expression of apoptosis-related proteins, G2/M cell cycle arrest and inhibition of JAK/STAT signalling pathway

| 认领 | 导出 |

文献详情

资源类型:
机构: [1]Department of Pharmacy,First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,650032,China [2]Department of Clinical Laboratory,First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,650032,China
出处:
ISSN:

关键词: Apoptosis Cell cycle Flow cytometry Linderalactone Lung carcinoma Protein expression

摘要:
Purpose: The main purpose of the current research work was to evaluate the antitumor effects of linderalactone in A-549 human lung carcinoma cell line along with the study its effects on apoptosis-related proteins, cell cycle phase distribution and JAK/STAT signalling pathway. Methods: The viability of lung cancer cell line was investigated by MTT assay at varying doses of linderalactone. Apoptosis was detected by using fluorescence microscopy and flow cytometry. Cell cycle analysis was carried out by flow cytometery. The protein expression was examined by western blotting. Results: Linderalactone could inhibit the proliferation of the lung cancer A-549 cells with an IC50 of 15 µM. Further investigations indicated the antiproliferative effects of linderalactone are due to apoptosis induction which was further confirmed by Bax and Bcl-2 expression. It also induced G2/M cell cycle arrest which was also associated with alteration of the expression of several important proteins. Furthermore, linderalactone could also suppress the JAK/STAT signalling pathway. Conclusions: In conclusion, linderalactone could be developed as a potential drug candidate against lung cancer provided that further in depth studies are carried out in this direction focusing on its in vivo efficacy. © 2019 Zerbinis Publications. All rights reserved.

语种:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
第一作者:
第一作者机构: [1]Department of Pharmacy,First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,650032,China
通讯作者:
通讯机构: [2]Department of Clinical Laboratory,First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,650032,China [*1]Department of Clinical Laboratory,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)